Three antihypertensive agents get green light for clinical trails

Published: 2007-09-13 07:00:00

Updated: 2007-09-13 07:00:00

The Korea Food and Drug Administration said that three drug makers were given the green light to conduct the clinical tests of three different antihypertensive drugs between August 29 and September 2.

1) Jeil Pharm: Phase II trials in hypertension with ACALAS (OJP-2028), a novel calcium channe...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK